Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor â palbociclib
Open original source